October 13, 2009 (FinancialWire) — Hana Biosciences (OTCBB: HNAB) has completed its previously disclosed private placement of units of its securities consisting of shares of common stock and warrants. Hana realized total gross cash proceeds of approximately $12.4 million.

Net proceeds of the offering will be used to support completion of Hana’s pivotal Phase 2 clinical trial (rALLy) of Marqibo in adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia and lymphoblastic lymphoma in second relapse or who failed two prior lines of treatment. The proceeds will also support Hana’s planned regulatory activities related to Marqibo including New Drug Application preparation and submission.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.